These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. NKG2D Enhances Double-Negative T Cell Regulation of B Cells. Hu SH; Zhang LH; Gao J; Guo JH; Xun XD; Xiang X; Cheng Q; Li Z; Zhu JY Front Immunol; 2021; 12():650788. PubMed ID: 34220808 [TBL] [Abstract][Full Text] [Related]
23. The natural killer-activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells. Talebian L; Fischer DA; Wu J; Channon JY; Sentman CL; Ernstoff MS; Meehan KR Transfusion; 2014 Jun; 54(6):1515-21. PubMed ID: 24446786 [TBL] [Abstract][Full Text] [Related]
24. Development of small molecule inhibitors of natural killer group 2D receptor (NKG2D). Wang J; Nakafuku KM; Ziff J; Gelin CF; Gholami H; Thompson AA; Karpowich NK; Limon L; Coate HR; Damm-Ganamet KL; Shih AY; Grant JC; Côte M; Mak PA; Pascual HA; Rives ML; Edwards JP; Venable JD; Venkatesan H; Shi Z; Allen SJ; Sharma S; Kung PP; Shireman BT Bioorg Med Chem Lett; 2023 Nov; 96():129492. PubMed ID: 37778428 [TBL] [Abstract][Full Text] [Related]
25. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8 Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217 [TBL] [Abstract][Full Text] [Related]
26. Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis. Zhu M; Huang Y; Bender ME; Girard L; Kollipara R; Eglenen-Polat B; Naito Y; Savage TK; Huffman KE; Koyama S; Kumanogoh A; Minna JD; Johnson JE; Akbay EA Cancer Res; 2021 Apr; 81(7):1813-1826. PubMed ID: 33495232 [TBL] [Abstract][Full Text] [Related]
28. NKG2D is a costimulatory receptor for human naive CD8+ T cells. Maasho K; Opoku-Anane J; Marusina AI; Coligan JE; Borrego F J Immunol; 2005 Apr; 174(8):4480-4. PubMed ID: 15814668 [TBL] [Abstract][Full Text] [Related]
29. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells. Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657 [TBL] [Abstract][Full Text] [Related]
30. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors. Maccalli C; Scaramuzza S; Parmiani G Cancer Immunol Immunother; 2009 May; 58(5):801-8. PubMed ID: 19089424 [TBL] [Abstract][Full Text] [Related]
36. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Waldhauer I; Steinle A Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567 [TBL] [Abstract][Full Text] [Related]
37. Interleukin-33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage-Mediated Shedding Mechanism. Wu J; Chen Z; Wickström SL; Gao J; He X; Jing X; Wu J; Du Q; Yang M; Chen Y; Zhang D; Yin X; Guo Z; Jensen L; Yang Y; Tao W; Lundqvist A; Kiessling R; Cao Y Adv Sci (Weinh); 2021 Nov; 8(21):e2101029. PubMed ID: 34486239 [TBL] [Abstract][Full Text] [Related]
38. KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a novel therapeutic target identified by enChIP. Alkhayer R; Ponath V; Frech M; Adhikary T; Graumann J; Neubauer A; von Strandmann EP Cell Commun Signal; 2023 May; 21(1):94. PubMed ID: 37143070 [TBL] [Abstract][Full Text] [Related]
39. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma. Wu JY; Ernstoff MS; Hill JM; Cole B; Meehan KR Cytotherapy; 2006; 8(2):141-8. PubMed ID: 16698687 [TBL] [Abstract][Full Text] [Related]
40. Immunogenetics of the NKG2D ligand gene family. Kasahara M; Yoshida S Immunogenetics; 2012 Dec; 64(12):855-67. PubMed ID: 22843249 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]